Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients

Masataka SawakiDepartment of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, JapanAbstract: Anti-HER2 agents, such as trastuzumab, lapatinib, trastuzumab emtansine (T-DM1), and pertuzumab, are standard agents in the treatment of breast cancer overexpressing the human epidermal growth factor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Sawaki M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ab485b74f2304aa78880c777589918a6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ab485b74f2304aa78880c777589918a6
record_format	dspace
spelling	oai:doaj.org-article:ab485b74f2304aa78880c777589918a62021-12-02T05:03:48ZTrastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients1179-1314https://doaj.org/article/ab485b74f2304aa78880c777589918a62014-04-01T00:00:00Zhttp://www.dovepress.com/trastuzumab-emtansine-in-the-treatment-of-her2-positive-metastatic-bre-a16469https://doaj.org/toc/1179-1314 Masataka SawakiDepartment of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, JapanAbstract: Anti-HER2 agents, such as trastuzumab, lapatinib, trastuzumab emtansine (T-DM1), and pertuzumab, are standard agents in the treatment of breast cancer overexpressing the human epidermal growth factor receptor 2 (HER2). Trastuzumab is the first approved HER2-targeted agent. Subsequent developments include agents with different mechanisms. In this paper, we review the results of clinical trials of T-DM1, a new anti-HER2 agent, with a focus on Japanese patients with breast cancer. On the basis of results from a Phase I study (JO22591), the maximum tolerated dose was determined to be 3.6 mg/kg every 3 weeks for both Japanese and western patients. In a Phase II study (JO22997), the overall response rate was 38.4% (90% confidence interval 28.8–48.6). T-DM1 was well tolerated in Japanese patients; however, the incidence of grade 3 or 4 thrombocytopenia was higher than that observed in earlier western studies, but was not associated with clinically important symptoms. Pharmacokinetic parameters for T-DM1 and its metabolites were consistent with those reported previously from a Phase I or II study in non-Japanese patients, and the data obtained showed no suggestion of ethnic differences. Several Phase III studies of T-DM1 are ongoing throughout the world, including in Japanese patients with breast cancer.Keywords: breast cancer, HER2/neu, trastuzumab emtansine, anti-HER2 therapySawaki MDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2014, Iss default, Pp 37-41 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Sawaki M Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
description	Masataka SawakiDepartment of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, JapanAbstract: Anti-HER2 agents, such as trastuzumab, lapatinib, trastuzumab emtansine (T-DM1), and pertuzumab, are standard agents in the treatment of breast cancer overexpressing the human epidermal growth factor receptor 2 (HER2). Trastuzumab is the first approved HER2-targeted agent. Subsequent developments include agents with different mechanisms. In this paper, we review the results of clinical trials of T-DM1, a new anti-HER2 agent, with a focus on Japanese patients with breast cancer. On the basis of results from a Phase I study (JO22591), the maximum tolerated dose was determined to be 3.6 mg/kg every 3 weeks for both Japanese and western patients. In a Phase II study (JO22997), the overall response rate was 38.4% (90% confidence interval 28.8–48.6). T-DM1 was well tolerated in Japanese patients; however, the incidence of grade 3 or 4 thrombocytopenia was higher than that observed in earlier western studies, but was not associated with clinically important symptoms. Pharmacokinetic parameters for T-DM1 and its metabolites were consistent with those reported previously from a Phase I or II study in non-Japanese patients, and the data obtained showed no suggestion of ethnic differences. Several Phase III studies of T-DM1 are ongoing throughout the world, including in Japanese patients with breast cancer.Keywords: breast cancer, HER2/neu, trastuzumab emtansine, anti-HER2 therapy
format	article
author	Sawaki M
author_facet	Sawaki M
author_sort	Sawaki M
title	Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
title_short	Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
title_full	Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
title_fullStr	Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
title_full_unstemmed	Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
title_sort	trastuzumab emtansine in the treatment of her2-positive metastatic breast cancer in japanese patients
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/ab485b74f2304aa78880c777589918a6
work_keys_str_mv	AT sawakim trastuzumabemtansineinthetreatmentofher2positivemetastaticbreastcancerinjapanesepatients
_version_	1718400668136374272

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients

Ejemplares similares